(Q43543300)

24 November 2017

title

A controlled trial of acyclovir in stable chronic HBsAg, HBeAg-positive carriers (English)

1 reference

24 November 2017

1 reference

Alexander GJ

1

1 reference

24 November 2017

Fagan EA

2

1 reference

24 November 2017

Hegarty JE

3

1 reference

24 November 2017

Rolando N

4

1 reference

24 November 2017

Guarner P

5

1 reference

24 November 2017

Eddleston AL

6

1 reference

24 November 2017

Williams R

7

1 reference

24 November 2017

publication date

1 January 1986

1 reference

24 November 2017

published in

Journal of Hepatology

1 reference

24 November 2017

volume

3 Suppl 2

1 reference

24 November 2017

page(s)

S123-7

1 reference

Seroconversion from Hepatitis B e Antigen to Antibody in Chronic Type B Hepatitis

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980110-6

7 January 2021

Antiviral Treatment of Chronic Hepatitis B Virus Infection. I. Changes in Viral Markers with Interferon Combined with Adenine Arabinoside

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980110-6

7 January 2021

Successful treatment of HBs and HBeAg positive chronic liver disease: prolonged inhibition of viral replication by highly soluble adenine arabinoside 5'-monophosphate (ARA-AMP).

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980110-6

7 January 2021

Spontaneous disappearance of viral replication and liver cell inflammation in HBsAg-positive chronic active hepatitis: results of a placebo vs. interferon trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980110-6

7 January 2021

Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980110-6

7 January 2021

Antiviral treatment of chronic hepatitis B virus infection: pharmacokinetics and side effects of interferon and adenine arabinoside alone and in combination

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980110-6

7 January 2021

Effect of liver disease on pharmacokinetics and toxicity of 9-beta-D-arabinofuranosyladenine-5-phosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980110-6

7 January 2021

Acyclovir in hepatitis B antigen-positive chronic liver disease: inhibition of viral replication and transient renal impairment with iv bolus administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980110-6

7 January 2021

Detection of hepatitis B virus DNA in serum by a simple spot hybridization technique: comparison with results for other viral markers.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980110-6

7 January 2021

Acyclovir inhibits hepatitis B virus replication in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980110-6

7 January 2021

Renal function after acyclovir intravenous injection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2886%2980110-6

7 January 2021

10.1016/S0168-8278(86)80110-6

Identifiers

DOI

1 reference

24 November 2017

1 reference